No Data
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Weak Earnings May Only Reveal A Part Of The Whole Picture
Fudan-Zhangjiang Bio-Pharmaceutical's Q2 Sales to Be Hit By Product Price Cuts
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK): The price reduction of Libaidu is not less than 35% compared to the previous bidding price.
Gelonghui reported on April 30 that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that its nanotechnology platform's antitumor drug, Doxorubicin Liposome Injection (trademark name: Liposomal Doxorubicin), was launched in August 2009. It is the first domestic generic of Doxil/Caelyx and the first generic nanodrug in both domestic and international markets. This drug utilizes advanced stealth liposome technology for encapsulation and features passive targeting characteristics. It represents an upgraded formulation of anthracycline drugs, offering advantages in cancer treatment, including enhanced efficacy, reduced cardiotoxicity, bone marrow suppression, and decreased hair loss.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH) reported a net income of 2.6651 million yuan in the first quarter, with a year-on-year growth of 13.53%.
Gelonghui, April 29丨Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH) released its first-quarter report, achieving total operating income of 0.18 billion yuan in the first quarter of 2025, a year-on-year increase of 21.85%; the net income attributable to shareholders of the parent company was 2.6651 million yuan, a year-on-year increase of 13.53%; the EPS was 0 yuan.
Fudan Zhangjiang: Fudan Zhangjiang Report for the First Quarter of 2025
Fudan Zhangjiang Report for the First Quarter of 2025